Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Phenotypic subtypes predict outcomes in colorectal cancer

Phenotypic subtypes predict outcomes in colorectal cancer Abstract Background Colorectal cancer (CRC) is the second leading cause of cancer-related deaths globally. The Colorectal Cancer Subtyping Consortium used the transcriptome-based method to classify CRC according to four molecular subtypes, each showing different genomic alterations and prognoses: CMS1 (microsatellite instable [MSI] immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal). To expedite the clinical implementation of such methods, easier and preferably tumor phenotype–based methods are needed. In this study, we describe a method to divide patients into four phenotypic subgroups using immunohistochemistry. Moreover, we analyze disease-specific survival (DSS) among different phenotypic subtypes and the associations between the phenotypic subtypes and clinicopathological variables. Methods We categorized 480 surgically treated CRC patients into four phenotypic subtypes (immune, canonical, metabolic, and mesenchymal) using the immunohistochemically determined CD3–CD8 tumor–stroma index, proliferation index, and tumor–stroma percentage. We analyzed survival rates for the phenotypic subtypes in different clinical patient subgroups using the Kaplan–Meier method and Cox regression analysis. Associations between phenotypic subtypes and clinicopathological variables were examined using the chi-square test. Results Patients with immune subtype tumors exhibited the best 5-year DSS, while mesenchymal subtype tumors accompanied the worst prognosis. The prognostic value of the canonical subtype showed wide variation among different clinical subgroups. Immune subtype tumors were associated with being female, stage I disease, and a right-side colon location. Metabolic tumors, however, were associated with pT3 and pT4 tumors, and being male. Finally, a mesenchymal subtype associated with stage IV disease, a mucinous histology, and a rectal tumor location. Conclusions Phenotypic subtype predicts patient outcome in CRC. Associations and prognostic values for subtypes resemble the transcriptome-based consensus molecular subtypes (CMS) classification. In our study, the immune subtype stood out with its exceptionally good prognosis. Moreover, the canonical subtype showed wide variability among clinical subgroups. Further studies are needed to investigate the concordance between transcriptome-based classification systems and the phenotypic subtypes. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Oncologica Taylor & Francis

Phenotypic subtypes predict outcomes in colorectal cancer

Download PDF
8 pages

Phenotypic subtypes predict outcomes in colorectal cancer

Abstract

Abstract Background Colorectal cancer (CRC) is the second leading cause of cancer-related deaths globally. The Colorectal Cancer Subtyping Consortium used the transcriptome-based method to classify CRC according to four molecular subtypes, each showing different genomic alterations and prognoses: CMS1 (microsatellite instable [MSI] immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal). To expedite the clinical implementation of such methods, easier and preferably tumor...
Loading next page...
 
/lp/taylor-francis/phenotypic-subtypes-predict-outcomes-in-colorectal-cancer-L0O5cQ2nM6
Publisher
Taylor & Francis
Copyright
© 2023 Acta Oncologica Foundation
ISSN
1651-226X
eISSN
0284-186X
DOI
10.1080/0284186X.2023.2183779
Publisher site
See Article on Publisher Site

Abstract

Abstract Background Colorectal cancer (CRC) is the second leading cause of cancer-related deaths globally. The Colorectal Cancer Subtyping Consortium used the transcriptome-based method to classify CRC according to four molecular subtypes, each showing different genomic alterations and prognoses: CMS1 (microsatellite instable [MSI] immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal). To expedite the clinical implementation of such methods, easier and preferably tumor phenotype–based methods are needed. In this study, we describe a method to divide patients into four phenotypic subgroups using immunohistochemistry. Moreover, we analyze disease-specific survival (DSS) among different phenotypic subtypes and the associations between the phenotypic subtypes and clinicopathological variables. Methods We categorized 480 surgically treated CRC patients into four phenotypic subtypes (immune, canonical, metabolic, and mesenchymal) using the immunohistochemically determined CD3–CD8 tumor–stroma index, proliferation index, and tumor–stroma percentage. We analyzed survival rates for the phenotypic subtypes in different clinical patient subgroups using the Kaplan–Meier method and Cox regression analysis. Associations between phenotypic subtypes and clinicopathological variables were examined using the chi-square test. Results Patients with immune subtype tumors exhibited the best 5-year DSS, while mesenchymal subtype tumors accompanied the worst prognosis. The prognostic value of the canonical subtype showed wide variation among different clinical subgroups. Immune subtype tumors were associated with being female, stage I disease, and a right-side colon location. Metabolic tumors, however, were associated with pT3 and pT4 tumors, and being male. Finally, a mesenchymal subtype associated with stage IV disease, a mucinous histology, and a rectal tumor location. Conclusions Phenotypic subtype predicts patient outcome in CRC. Associations and prognostic values for subtypes resemble the transcriptome-based consensus molecular subtypes (CMS) classification. In our study, the immune subtype stood out with its exceptionally good prognosis. Moreover, the canonical subtype showed wide variability among clinical subgroups. Further studies are needed to investigate the concordance between transcriptome-based classification systems and the phenotypic subtypes.

Journal

Acta Oncologica – Taylor & Francis

Published: Mar 4, 2023

Keywords: Phenotypic subtype; CMS; consensus molecular subtypes; colorectal cancer; colon cancer; rectal cancer; immunohistochemistry

References

  • Global patterns and trends in colorectal cancer incidence and mortality
  • Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  • The consensus molecular subtypes of colorectal cancer
  • Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition
  • Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer
  • Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines
  • A colorectal cancer classification system that associates cellular phenotype and responses to therapy
  • Poor-prognosis Colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
  • Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value
  • Colorectal cancer subtypes : Translation to routine clinical pathology
  • A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry
  • Classification of colorectal cancer in molecular subtypes by immunohistochemistry
  • Clinical relevance of microsatellite instability in colorectal cancer
  • Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
  • The immunoscore: colon cancer and beyond
  • The clinical utility of microsatellite instability in colorectal cancer
  • Molecular genetics and targeted therapy of WNT-related human diseases
  • Evaluation of cell proliferation in breast carcinoma; comparison of Ki-67 lmmunohistochemical study, DNA flow cytometric analysis, and mitotic count
  • The tumour–stroma ratio in colon cancer: the biologigal role and its prognostic impact
  • FGFR4 promotes stroma-induced epithelial-to-mesenchymal transition in colorectal cancer
  • Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells
  • Hypoxic and ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids
  • Oncogenic KRAS maintains pancreatic tumors through regulation of anabolic glucose metabolism Haoqiang
  • Molecular pathways and cellular metabolism in colorectal cancer
  • Tumor-associated CD3- and CD8-positive immune cells in colorectal cancer: the additional prognostic value of CD8+-to-CD3+ ratio remains debatable
  • The immune score as a new possible approach for the classification of cancer
  • Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer
  • Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
  • The impact of age on colorectal cancer incidence, treatment, and outcomes in an equal-access health care system
  • Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes Jonathan
  • Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC‑8 stratification
  • Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer
  • Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis